fregime
TODAYSTOCKSARCHIVEABOUTGUIDE
Sign inFollow your stocks

Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 26 Aug 2026

BSE, full dossier

BSE Limited and National Stock Exchange of India Limited have granted in-principle approvals for a proposed Rights Issue of Fully paid-up Equity Shares of Sadhana Nitrochem Limited aggregating up to Rs. 26352.92 Lakhs.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

BSE Limited and National Stock Exchange of India Limited have granted in-principle approvals for a proposed Rights Issue of Fully paid-up Equity Shares of Sadhana Nitrochem Limited aggregating up to Rs. 26352.92 Lakhs.

bseindia.com13 Feb 2026

A single act of reporting so far, corroborating sources join this record as they publish.

BSE

₹3,046.00

▼ -1.49%

Close (EOD), as of 1 Oct 2026 · source

BSE: results, dividends, orders, the full cited record →

More on BSE

BSE shares plummeted 3.5% to ₹ 3,092, losing previous gains after entering Nifty 50, as stake sales by Goldman Sachs and BNP Paribas counteracted positive inclusion effects.

1 Oct 2026 · 1 publisher

Shares of the Bombay Stock Exchange (BSE) Ltd. will begin trading on the Nifty 50 index from Wednesday, September 30.

30 Sep 2026 · 1 publisher

Goldman Sachs and BNP Paribas sold a combined 1.67% stake in BSE for ₹2,186.44 crore through separate bulk deals.

30 Sep 2026 · 2 publishers

BSE share price was under pressure on Wednesday, September 30, falling nearly 4 per cent in early trade as the stock began trading on the benchmark Nifty 50 index for the first time.

30 Sep 2026 · 1 publisher

BSE shares rose 1.6 percent to ₹3,147.50 on the NSE on Tuesday as the stock is set to replace Wipro in the Nifty 50 index.

29 Sep 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.